COMPANY
FDA-approved therapeutic company
Location: Solana Beach, CA · source · Oct 15, 2026
Profile checked Oct 10, 2026
Keywords: Menkes Disease Long Term Follow-Up copper histidinate
Timeline
- FDA FDA New drug/biologic (novel): ZYCUBO (copper histidinate) — NDA211241, Jan 12, 2026. Applicant at approval: Sentynl Therapeutics, Inc. source ↗
- Trial start —: Long Term Follow-up on Menkes Disease Patients source ↗
Clinical trials (lead sponsor) 2
| Record | Title | Phase | Status | Start | Primary completion |
|---|
| NCT04337684 | Long Term Follow-up on Menkes Disease Patients | Not listed | Active, not recruiting | Dec 1, 2019 | Feb 26, 2026 (actual) |
| NCT04074512 | Copper Histidinate Treatment for Menkes Disease | Not listed | Approved for marketing | Not listed | Not listed |
FDA records (last 2 years)
- FDA New drug/biologic (novel): ZYCUBO (copper histidinate) — NDA211241, Jan 12, 2026. Applicant at approval: Sentynl Therapeutics, Inc. source ↗
Connect
See your connections at Sentynl Therapeutics on LinkedIn (search by name, results not checked)LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.
LinkedIn page linked from the company's own site: source · seen 2026-10-12
